« Previous Abstract"Impact of Salting Techniques on the Physio-Chemical Characteristics, Sensory Properties, and Volatile Organic Compounds of Ras Cheese"    Next AbstractDemonstrated solid-state stability of parathyroid hormone PTH(1-34) coated on a novel transdermal microprojection delivery system »

Molecules

Title:		The Ameliorative Effect of Empagliflozin in Vigabatrin-Induced Cerebellar/Neurobehavioral Deficits: Targeting mTOR/AMPK/SIRT-1 Signaling Pathways
Author(s):		Amer RM; Eltokhy AK; Elesawy RO; Barakat AN; Basha E; Eldeeb OS; Aboalsoud A; Elgharabawy NM; Ismail R;
Address:		"Anatomy and Embryology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Medical Biochemistry Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Pharmacology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Pediatric Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Physiology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt"
Journal Title:		Molecules
Year:		2022
Volume:		20220607
Issue:		12
Page Number:		-
DOI:		10.3390/molecules27123659
ISSN/ISBN:		1420-3049 (Electronic) 1420-3049 (Linking)
Abstract:		"Introduction. Vigabatrin (VGB) is an antiepileptic drug that acts to irreversibly inhibit the gamma-aminobutyric acid (GABA) transaminase enzyme, elevating GABA levels. Broad studies have established that long-term treatment and/or high doses of VGB lead to variable visual defects. However, little attention has been paid to its other side effects, especially those demonstrating cerebellar involvement. Sodium glucose-linked co-transporter 2 (SGLT2) inhibitors are antidiabetic agents with protective effects far greater than expected based on their anti-hyperglycemic effect. Method. Our study herein was designed to investigate the possible ameliorative effect of empagliflozin, the SGLT2 inhibitors, in VGB-induced cerebellar toxicity. A total of 40 male Wistar rats were allocated equally into 4 groups: Group I: control group; Group II: VGB group; Group III empagliflozin treated VGB group; and Group IV: empagliflozin treated group. All groups were subjected to the detection of cerebellar messenger RNA gene expression of silent mating type information regulation 2 homolog 1 (SIRT1) and Nucleoporin p62 (P62). Mammalian target of rapamycin (mTOR), adenosine monophosphate-activated protein kinase (AMPK), and beclin1 levels were assessed by the ELISA technique while malondialdehyde (MDA) level and superoxide dismutase (SOD) activity were detected spectrophotometrically. Immuno-histochemical studies, focusing on glial fibrillary acidic protein (GFAP) and S100 were performed, and the optical color density and the mean area percentage of GFAP positive astrocytes and the number of S 100 positive cells were also counted. Results. Following empagliflozin treatment, we documented significant upregulation of both SIRT1 and P62 mRNA gene expression. Additionally, AMPK, Beclin1 levels, and SOD activity were significantly improved, while both mTOR and MDA levels were significantly reduced. Conclusions. We concluded for the first time that empagliflozin efficiently ameliorated the VGB-induced disrupted mTOR/AMPK/SIRT-1 signaling axis with subsequent improvement of the autophagy machinery and mitigation of the oxidative and inflammatory cellular environment, paving the way for an innovative therapeutic potential in managing VGB-induced neurotoxicity"
Keywords:		"*AMP-Activated Protein Kinases Animals Anticonvulsants/pharmacology Beclin-1 Benzhydryl Compounds Glucosides Male Mammals Rats Rats, Wistar Signal Transduction Sirtuin 1/genetics Superoxide Dismutase TOR Serine-Threonine Kinases *Vigabatrin/adverse effect;"
Notes:		"MedlineAmer, Rabab M Eltokhy, Amira Kamel Elesawy, Rasha Osama Barakat, Amany Nagy Basha, Eman Eldeeb, Omnia Safwat Aboalsoud, Alshimaa Elgharabawy, Nancy Mohamed Ismail, Radwa eng Switzerland 2022/06/25 Molecules. 2022 Jun 7; 27(12):3659. doi: 10.3390/molecules27123659"